Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCOPR Newswire·May 30 at 08:51 AM06990+0.58%002422+1.52%
Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026PR Newswire·May 21 at 07:00 PM002422+1.52%FBT-3.39%
Huilun Pharmaceutical rushes to the Hong Kong stock market: annual revenue of 690 million, net loss of 170 million, many family members of Dong Dalun hold shares雷帝触网·Apr 3 at 05:10 AM002422+1.52%
CITIC International raised the target price of KELUN PHARMA to 507.11 yuan, rating it as "Buy."AASTOCKS·Mar 25 at 03:29 AM516820+0.58%516500+0.65%
In "The Big Banks," Citigroup lowered the target price for KELUN PHARMA to 500.7 yuan with a rating of "Outperform the Market."AASTOCKS·Mar 24 at 11:15 PM520880-0.46%002422+1.52%
22:31 ETKELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFFprnewswire·Mar 23 at 09:32 PM588250+0.91%588130+0.82%
Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 ResultsTip Ranks·Mar 11 at 06:40 AM510660+0.86%1595060.00%
06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitisprnewswire·Mar 9 at 05:48 AM510660+0.86%159102+0.40%
Mainland China’s investors pour into Hong Kong-listed drug stocksSCMP·Feb 9 at 11:34 PM002422+1.52%06990+0.58%
